609 related articles for article (PubMed ID: 16273304)
21. Adenovirus-mediated gene transfer of caspase-8 sensitizes human adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand.
Yasui H; Adachi M; Hamada H; Imai K
Int J Oncol; 2005 Feb; 26(2):537-44. PubMed ID: 15645141
[TBL] [Abstract][Full Text] [Related]
22. [Construction and study of replication-defective adenovirus targeting hepatocarcinoma].
Xu DY; Du ZY; Wang Y; Chen HH; Xu YJ; Lu YL
Ai Zheng; 2006 Jul; 25(7):798-804. PubMed ID: 16831267
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand.
Reddy RM; Tsai WS; Ziauddin MF; Zuo J; Cole GW; Maxhimer JB; Fang B; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):883-91. PubMed ID: 15573073
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B
Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894
[TBL] [Abstract][Full Text] [Related]
25. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
Armeanu S; Lauer UM; Smirnow I; Schenk M; Weiss TS; Gregor M; Bitzer M
Cancer Res; 2003 May; 63(10):2369-72. PubMed ID: 12750253
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
27. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
28. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
[TBL] [Abstract][Full Text] [Related]
29. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
[TBL] [Abstract][Full Text] [Related]
30. Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter.
Mawatari F; Tsuruta S; Ido A; Ueki T; Nakao K; Kato Y; Tamaoki T; Ishii N; Nakata K
Cancer Gene Ther; 1998; 5(5):301-6. PubMed ID: 9824049
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect.
Seol JY; Park KH; Hwang CI; Park WY; Yoo CG; Kim YW; Han SK; Shim YS; Lee CT
Cancer Gene Ther; 2003 Jul; 10(7):540-8. PubMed ID: 12833134
[TBL] [Abstract][Full Text] [Related]
32. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
VanOosten RL; Earel JK; Griffith TS
Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL.
Burroughs KD; Kayda DB; Sakhuja K; Hudson Y; Jakubczak J; Bristol JA; Ennist D; Hallenbeck P; Kaleko M; Connelly S
Cancer Gene Ther; 2004 Feb; 11(2):92-102. PubMed ID: 14730331
[TBL] [Abstract][Full Text] [Related]
35. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
36. Insulation from viral transcriptional regulatory elements enables improvement to hepatoma-specific gene expression from adenovirus vectors.
Ye X; Liang M; Meng X; Ren X; Chen H; Li ZY; Ni S; Lieber A; Hu F
Biochem Biophys Res Commun; 2003 Aug; 307(4):759-64. PubMed ID: 12878174
[TBL] [Abstract][Full Text] [Related]
37. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.
Mohr A; Henderson G; Dudus L; Herr I; Kuerschner T; Debatin KM; Weiher H; Fisher KJ; Zwacka RM
Gene Ther; 2004 Mar; 11(6):534-43. PubMed ID: 14999225
[TBL] [Abstract][Full Text] [Related]
38. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.
Ohashi M; Kanai F; Tateishi K; Taniguchi H; Marignani PA; Yoshida Y; Shiratori Y; Hamada H; Omata M
Biochem Biophys Res Commun; 2001 Mar; 282(2):529-35. PubMed ID: 11401492
[TBL] [Abstract][Full Text] [Related]
39. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Liu J; Fang B
Int J Oncol; 2003 Jun; 22(6):1241-5. PubMed ID: 12738989
[TBL] [Abstract][Full Text] [Related]
40. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
